Castle Biosciences
Presence
Castle Biosciences is one of the...
Castle Biosciences is a company listed under the stock ticker CSTL (US).
Executives
View the org chart displaying its 31 main executives
Most searched biographies at Castle Biosciences
- Derek Maetzold, Director, President and Chief Executive Officer
- Mara Aspinall, Director
- Miles Harrison, Director
Popular executive movements at Castle Biosciences
- Rodney Cotton has joined the company as Director (posted on March 29 2024).
Create your alert
to follow the executive moves at Castle Biosciences.
Biotechnology
Castle Biosciences has 2,292 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Lycia Therapeutics has just announced a $107 Million fundraising (posted on May 15 2024).
- Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on May 13 2024).
Popular contacts in Biotechnology
News
Press releases by Castle Biosciences
- Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
- Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
- Castle Biosciences Announces Updates to its Board of Directors
- Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
- In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
- Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
- Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
- New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
- Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
- View more press releases Close
Social media about Castle Biosciences
- Castle Biosciences on Wikipedia, Google News & Yahoo Finance
- Castle Biosciences on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Derek Maetzold 
Call Castle Biosciences at +1 866...
